Pablo Cagnoni is president and chief executive officer of Rubius Therapeutics. Over the course of Pablo’s career as an oncologist and pharmaceutical executive, he has been committed to advancing the development of breakthrough treatments for people with cancer and other diseases. He has played a key role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor®, Kyprolis® and Tarceva®.
Before joining Rubius in 2018, Pablo served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer. He joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to $1.5 billion. Prior to Tizona, he served as President of Onyx Pharmaceuticals (acquired by Amgen), where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).
Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Pablo earned his medical degree from University of Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
He is a member of the Board of Directors for Fusion Pharmaceuticals, Laronde, Repertoire Immune Medicines and Synthekine. He serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He previously served as a board member for CRISPR Therapeutics, Harpoon Therapeutics, Tizona Therapeutics and Tango Therapeutics and was Executive Chairman of Blade Therapeutics.
What is Pablo J. Cagnoni's net worth?
The estimated net worth of Pablo J. Cagnoni is at least $4,248.21 as of January 31st, 2023. Dr. Cagnoni owns 74,530 shares of Rubius Therapeutics stock worth more than $4,248 as of April 25th. This net worth evaluation does not reflect any other assets that Dr. Cagnoni may own. Learn More about Pablo J. Cagnoni's net worth.
How do I contact Pablo J. Cagnoni?
Has Pablo J. Cagnoni been buying or selling shares of Rubius Therapeutics?
Pablo J. Cagnoni has not been actively trading shares of Rubius Therapeutics during the past quarter. Most recently, Pablo J. Cagnoni sold 7,240 shares of the business's stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $0.24, for a transaction totalling $1,737.60. Following the completion of the sale, the director now directly owns 74,530 shares of the company's stock, valued at $17,887.20. Learn More on Pablo J. Cagnoni's trading history.
Who are Rubius Therapeutics' active insiders?
